The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...